Aclarion(US:ACON) Globenewswireยท2025-10-07 10:00Core Insights - Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH, highlighting its innovative contributions to healthcare technology [1][4]. Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary AI algorithms to enhance clinical treatments [7]. - The company's flagship product, Nociscan, is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3][7]. Product Details - Nociscan transforms MR spectroscopy signals into objective biomarkers associated with disc pain, providing actionable insights for personalized treatment plans [3][7]. - An estimated 266 million people globally suffer from chronic low back pain, indicating a significant market opportunity for Aclarion's solutions [3]. Recognition and Impact - The recognition as a finalist from over 1,800 submissions underscores Aclarion's commitment to improving healthcare efficiency and equity through digital innovations [4][6]. - CEO Brent Ness emphasized that this acknowledgment reflects the company's vision and determination to make Nociscan widely available to those affected by chronic low back pain [4].